Arteriotomy Closure Devices Market By Product Type (Suture-Mediated Closure Devices, Collagen Plug and Anchor Devices, Synthetic Sealant and Extravascular Closure Devices, Mechanical Clip Closure Devices, Patch-Based Large-Bore Closure Systems); By Application (Coronary Angiography and Percutaneous Coronary Intervention, Structural Heart Procedures, Peripheral Vascular Interventions, Endovascular Aneurysm Repair, Neurointerventional Procedures, Interventional Radiology Procedures, Mechanical Circulatory Support Procedures); By End User (Hospitals and Catheterization Laboratories, Cardiovascular and Structural Heart Centers, Ambulatory Cardiovascular Centers, Interventional Radiology Centers, Vascular Surgery Centers); By Access Size (Small-Bore Arterial Closure, Mid-Bore Arterial Closure, Large-Bore Arterial Closure); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Arteriotomy Closure Devices Market: Large-Bore Procedures and Cath-Lab Efficiency Shift Demand Toward Premium Femoral Closure

The Global Arteriotomy Closure Devices Market was valued at USD 1.30 billion in 2025 and is projected to reach USD 2.14 billion by 2032, expanding at a CAGR of 7.4%, according to Strategic Market Research.

 

Femoral arterial access sites require reliable closure after catheter-based procedures. Key device options include suture-mediated systems, collagen plugs, synthetic sealants, mechanical clips and large-bore closure platforms that reduce compression time, support earlier mobilisation and improve catheterization-lab efficiency.

 

Market demand is driven by femoral-access procedure volumes rather than cardiovascular disease prevalence alone. Key factors include sheath size, intervention complexity, discharge practices and physician preference, with large-bore procedures such as TAVR creating greater closure-device demand than routine diagnostic angiography.

 

Radial-First PCI Is Reducing Routine Femoral Closure Volume

The shift from femoral to radial access is the main structural restraint on conventional arteriotomy closure devices. An analysis of 6,658,479 U.S. PCI procedures performed between January 2013 and June 2022 found that radial access increased from 20% to 58%, surpassing femoral access. Radial procedures were also associated with lower in-hospital mortality, major bleeding and vascular complications.

Coronary angiography and percutaneous coronary intervention remained the largest application segment in 2025, accounting for an estimated 42% share and USD 546 million in revenue. However, the segment is forecast to expand at a comparatively moderate 4.5% CAGR from 2026 to 2032 as radial access replaces femoral closure in a growing proportion of uncomplicated coronary procedures.

Companies focused on standard 5F to 8F femoral closure devices face pressure as radial access expands. Femoral access remains important for complex coronary interventions, peripheral vascular procedures, structural-heart treatments and cases requiring larger equipment. The market is therefore shifting from routine low-complexity closures toward fewer but higher-value large-bore and specialist applications.

 

Large-Bore Procedures Are Raising Device Value per Case

Large-bore procedures such as TAVR, endovascular aneurysm repair and mechanical circulatory support require more demanding femoral-access closure than routine coronary angiography. Closure failure can result in prolonged compression, additional devices, transfusion, vascular repair, surgery or extended hospitalization.

Large-bore arterial closure represented an estimated 34% of the market and USD 442 million in 2025 revenue. It is projected to record the fastest access-size CAGR of 10.7% through 2032, compared with 6.7% for mid-bore closure and 4.8% for small-bore products.

The FDA-approved MANTA Vascular Closure Device illustrates the commercial separation between routine and large-bore closure. The 14F MANTA is indicated after the use of 10F to 14F devices or sheaths, while the 18F MANTA covers access created by 15F to 18F devices or sheaths, with a maximum outer profile of 25F.

Abbott’s Perclose ProGlide and Perclose ProStyle systems cover common femoral arterial access sites using 5F to 21F sheaths. For arterial sheaths larger than 8F, FDA labeling requires at least two devices and the pre-close technique. This broad indication supports Abbott across routine catheterization and structural-heart procedures, although multi-device closure creates additional product use and procedural planning.

Structural-heart procedures accounted for approximately 22% of the application market and USD 286 million in 2025 revenue. Supported by TAVR and other transfemoral interventions, the segment is projected to expand at a 10.9% CAGR through 2032.

Endovascular aneurysm repair generated an estimated USD 130 million, equal to a 10% market share, and is forecast to grow at an 8.8% CAGR. Mechanical circulatory-support procedures represented a smaller 4% share and USD 52 million, but are projected to expand at a 10.5% CAGR as large-bore access is increasingly used during complex cardiac care.

 

Hospitals Buy Faster Recovery, Not Guaranteed Elimination of Bleeding

Earlier ambulation and shorter recovery are the main economic benefits of arteriotomy closure devices. A meta-analysis of 14,401 randomized patients found that these devices reduced time to hemostasis and ambulation after transfemoral procedures, although they did not lower overall bleeding rates.

Their value therefore lies primarily in workflow efficiency. Compared with manual compression, closure devices can reduce staff monitoring, shorten patient immobilization and support more predictable recovery and discharge.

Hospitals and general catheterization laboratories held the largest end-user share at an estimated 62%, equivalent to USD 806 million in 2025. The segment is projected to grow at a 6.1% CAGR through 2032, supported by its large installed procedure base.

Dedicated cardiovascular and structural-heart centers accounted for approximately 19% and USD 247 million, with a stronger projected 9.4% CAGR. These facilities perform a greater concentration of TAVR, complex PCI, aneurysm repair, and other procedures requiring premium closure devices.

Ambulatory cardiovascular centers represented 12% of the market and USD 156 million. This segment is forecast to record the fastest end-user CAGR of 10.1% because prolonged observation directly limits the number of patients that can be treated during the day. Interventional-radiology and vascular-surgery centers held the remaining 7% share and USD 91 million, with an estimated 7.5% CAGR.

Haemonetics markets a performance guarantee for its VASCADE system that provides financial reimbursement in qualifying device-related complication cases. The company reports that VASCADE technology has been used in more than 500,000 procedures. Such risk-sharing arrangements connect device purchasing to hospital economics.

 

Suture-Mediated Devices Retain the Largest Product Share

Suture-mediated closure devices held an estimated 39% market share and generated USD 507 million in 2025, making them the largest product category. The segment is projected to expand at a 7.0% CAGR through 2032.

Their position reflects broad access-size coverage, physician familiarity, and suitability for pre-close strategies before large-bore equipment is introduced. Abbott’s Perclose platform is used across coronary, peripheral, structural-heart, and other femoral-access procedures.

Abbott also sells the StarClose SE system for common femoral artery access created with 5F or 6F sheaths. StarClose uses an extravascular nitinol clip and is indicated for reducing time to hemostasis and ambulation.

Mechanical clip devices accounted for a smaller 8% share and USD 104 million in 2025. The category is projected to grow at a 4.2% CAGR, reflecting its narrower sheath-size coverage and competition from bioabsorbable sealants.

 

Collagen and Sealant Systems Compete on Procedural Consistency

Collagen plug and anchor devices represented approximately 26% of the market and USD 338 million in 2025 revenue. The segment is projected to expand at a 5.5% CAGR through 2032.

Terumo’s ANGIO-SEAL VIP combines an internal anchor with an external collagen component and is available in 6F and 8F configurations. Terumo reports 99.7% deployment success and 97.8% device-based hemostasis in the supporting evidence cited on its platform.

In August 2025, Terumo opened a 64,000-square-foot manufacturing facility in Puerto Rico to meet increasing ANGIO-SEAL demand. The company invested USD 45 million, expected to add approximately 180 jobs, and stated that the device had been used in more than 10 million patients worldwide.

Synthetic sealant and extravascular closure devices accounted for an estimated 14% share and USD 182 million. This category is forecast to expand at a 7.2% CAGR.

Cordis competes through MYNX CONTROL, which uses a resorbable polyethylene glycol sealant and is available for 5F, 6F, and 7F femoral arterial access. Its extravascular design leaves no permanent clip or suture at the access site.

 

Patch-Based Closure Is the Fastest-Growing Product Category

Patch-based large-bore closure systems represented approximately 13% of the market and USD 169 million in 2025. Although smaller than suture and collagen products, the segment is projected to record the highest product CAGR of 13.1% through 2032.

Haemonetics acquired Vivasure Medical in January 2026 for an upfront payment of EUR 100 million, with up to EUR 85 million in milestone-based consideration. Vivasure’s PerQseal Elite uses a fully absorbable, sutureless patch for large-bore arteriotomies and venotomies up to 26F.

The company submitted a U.S. premarket approval application for the arterial system in 2025 and received European CE Mark approval for arterial and venous indications. PerQseal Elite was not available for sale in the United States at the time of the acquisition announcement.

The transaction gives Haemonetics a potential entry into premium structural-heart and endovascular closure and demonstrates the strategic value assigned to large-bore technologies that avoid multiple sutures or permanent implants.

 

North America Leads While Asia-Pacific Records Faster Expansion

North America held an estimated 41% share of the global market, equivalent to USD 533 million in 2025. The region is projected to expand at a 6.5% CAGR through 2032. Its position is supported by established catheterization infrastructure, high structural-heart procedure volumes, same-day discharge programs, and early adoption of premium closure systems.

Europe represented approximately 27% and USD 351 million, with a projected 6.6% CAGR. Demand is supported by mature interventional cardiology networks, TAVR adoption, and access to CE-marked large-bore technologies that may not yet be commercially available in the United States.

Asia-Pacific accounted for an estimated 23% share and USD 299 million in 2025. It is forecast to record the fastest regional CAGR of 9.8%, supported by expanding cardiovascular treatment capacity, higher procedure volumes in China and India, hospital infrastructure investment, and growing access to minimally invasive interventions.

Latin America held approximately 5% of the market and USD 65 million, with a projected 7.9% CAGR. The Middle East and Africa accounted for the remaining 4% and USD 52 million, with an estimated 7.4% CAGR.

 

Market Growth Will Come from Procedure Mix Rather Than Uniform Unit Expansion

Routine femoral PCI closure faces continued substitution from radial access. The larger commercial opportunity is shifting toward structural-heart interventions, complex peripheral procedures, endovascular aneurysm repair, mechanical circulatory support, and other large-bore cases where femoral access remains central.

Revenue growth can exceed unit growth because large-bore procedures use premium devices and may require multiple closure products, ancillary equipment, or rescue support. Hospitals also place greater value on products that support predictable recovery and reduce unplanned intervention.

Bioabsorbable implants, sutureless patches and single-device large-bore closure are becoming key areas of competition. Leading Companies will be differentiatated through wider sheath-size coverage, strong clinical evidence, reliable manufacturing, procedural support and purchasing models linked to hospital outcomes.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 1.30 Billion
Revenue Forecast in 2032	USD 2.14 Billion
Overall Growth Rate	CAGR of 7.4% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Product Type, By Application, By End User, By Access Size, By Geography
By Product Type	Suture-Mediated Closure Devices, Collagen Plug and Anchor Devices, Synthetic Sealant and Extravascular Closure Devices, Mechanical Clip Closure Devices, Patch-Based Large-Bore Closure Systems
By Application	Coronary Angiography and Percutaneous Coronary Intervention, Structural Heart Procedures, Peripheral Vascular Interventions, Endovascular Aneurysm Repair, Neurointerventional Procedures, Interventional Radiology Procedures, Mechanical Circulatory Support Procedures
By End User	Hospitals and Catheterization Laboratories, Cardiovascular and Structural Heart Centers, Ambulatory Cardiovascular Centers, Interventional Radiology Centers, Vascular Surgery Centers
By Access Size	Small-Bore Arterial Closure, Mid-Bore Arterial Closure, Large-Bore Arterial Closure
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising volume of catheter-based cardiovascular and peripheral vascular procedures; growing use of large-bore access in structural heart and mechanical circulatory support interventions; increasing preference for faster hemostasis, earlier patient mobilization, and shorter hospital stays; continued development of extravascular and suture-mediated closure technologies
Customization Option	Available upon request